Advertisement
Advertisement
NBTX
Nanobiotix S.A. - ADR
30.63
USDSponsored
+0.61
+2.03%
Nov 06, 15:59 UTC -5
Closed
After-Market
30.65
+0.02
+0.07%
Nanobiotix S.A. - ADR (NBTX) Earnings
NBTX Earnings Reports
Positive Surprise Ratio
NBTX beat 4 of 17 last estimates.
24%
Next Report
Date of Next Report
Nov 23, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Nanobiotix S.A. - ADR earnings per share and revenue
On Sep 25, 2026, NBTX reported earnings of -0.70 USD per share (EPS) for Q2 26, missing the estimate of -0.11 USD, resulting in a -496.76% surprise. Revenue reached 5.55 million, compared to an expected 30.50 million, with a -81.80% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Nanobiotix S.A. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Nanobiotix S.A. - ADR reported EPS of -$0.70, missing estimates by -496.76%, and revenue of $5.55M, -81.8% below expectations.
How did the market react to Nanobiotix S.A. - ADR's Q2 2026 earnings?
The stock price moved down -0.45%, changed from $33.46 before the earnings release to $33.31 the day after.
When is Nanobiotix S.A. - ADR expected to report next?
The next earning report is scheduled for Nov 23, 2026.
What are the forecasts for Nanobiotix S.A. - ADR's next earnings report?
Based on --
analysts, Nanobiotix S.A. - ADR is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.